Mark Haden, psychedelic medicine expert, joins Clearmind


Toronto, August 03, 2021 (GLOBE NEWSWIRE) – Clearmind Medicine Inc. (CSE: CMND) (“Clear mind“or the”Company“), a psychedelic medicine biotechnology company focused on the discovery and development of novel therapies derived from psychedelics to solve widespread and outsourced health problems, announces that Mark Haden has joined the company’s scientific advisory board (the “SAB“). The initial purpose of the SAB will be to provide advice on the Company’s request for a US Food and Drug Administration Investigational New Drug Review (“FDA“) for MEAI, for the treatment of alcohol-related disorders (“EUR“).

A recognized leader in the field, Mr. Haden has dedicated his career to advancing the use of psychedelics in medicine. He is currently Director of Clinical Research at Psygen Industries, a manufacturer of pharmaceutical grade psychedelic pharmaceuticals for clinical research and therapeutic applications and is an Assistant Professor in the School of Population and Public Health at the University of British Columbia. .

Mr. Haden has extensive research experience, including a leadership role in the Psilocybin Research Investigating Medical Efficacy (PRIME) study, which explores psilocybin as an adjuvant in the treatment of substance use disorders. , and he spent 10 years as chairman and executive director. from MAPS Canada (Multidisciplinary Association for Psychedelic Studies), an organization he founded. He has also spent over 25 years working directly with patients through the Vancouver Coastal Health Addiction Services at the Pacific Spirit Community Health Center.

He is a frequent keynote speaker on the subject of psychedelics and has been published in several journals including the Canadian Journal of Public Health, International Journal of Drug Policy, Encyclopedia of Public Health, Harm Reduction Journal, Open Medicine, Journal of Psychoactive . Drugs and Journal of Studies on Alcohol and Drugs. He has also been instrumental in helping the Health Officers Council of British Columbia develop its position papers, conferences and presentations on issues relating to the regulation of illegal drugs.

“Mark is an important addition to our SAB. He is one of the world’s leading advocates for the legalization of psychedelics and a strong supporter of their medicinal value. His research on psychedelics and their potential to treat drug addiction parallels the work we do to develop therapies to manage AUD, and I am confident that his contribution to our efforts to gain FDA approval for MEAI will be invaluable, ”commented Adi Zuloff-Shani, Ph.D., CEO of Clearmind.

Mr. Haden noted, “Clearmind’s innovative approach to harnessing the properties of psychedelics to create therapies for mental health issues has the potential to change millions of lives around the world. I have dedicated my career to a similar quest and am delighted to facilitate this effort in any way I can. I look forward to working with the talented team at Clearmind as well as the other distinguished members of the Advisory Board.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotechnology company focused on the discovery and development of novel therapies derived from psychedelics to address widespread and underserved health issues, including alcohol use disorders. Its main objective is to research and develop compounds based on psychedelics and to attempt to market them as regulated drugs, foods or supplements.

The Company’s intellectual portfolio currently consists of two families of patents. The first, “Binge Behavior Regulators,” has been granted in the United States, Europe, China and India, with pending divisional applications in Europe and the United States. The second, “Alcohol Beverage Substitute”, has been approved for a European patent, with applications in the United States, China and India. The Company intends to apply for additional patents for its compounds whenever warranted and will remain opportunistic in acquiring additional intellectual property to build its portfolio.

Clearmind’s shares are listed on the Canadian Securities Exchange under the symbol “CMND”.

For more information, please contact:
Investor Relations,
Telephone: (778) 400-5347
General Information,


This press release may contain forward-looking statements and information based on current expectations. These statements should not be interpreted as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those implied by such statements. These statements include submitting the relevant documentation on time to the satisfaction of the relevant regulators and raising sufficient funds to carry out the Company’s business strategy. There is no certainty that any of these events will occur. Although these statements are based on reasonable assumptions of management, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.

Investing in early stage companies inherently involves a high degree of risk, and investing in securities of the Company will be considered highly speculative.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and there will be no sale of securities in any province where such an offer, solicitation or sale would be illegal.

Neither the Canadian Securities Exchange (the “CST”) Nor its regulatory services provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Source link

Leave A Reply

Your email address will not be published.